Plan B Emergency Contraception Has Less Nausea Than Yuzpe Regimen
Executive Summary
Women's Capital Corp.' s Plan B (levonorgestrel) emergency contraception, approved by FDA July 28, produced less nausea and vomiting than the Yuzpe levonorgestrel/estradiol regimen, currently marketed by Gynetics as Preven.
You may also be interested in...
Gynetics Exec Supports Restricted Access For OTC Emergency Contraceptives
Emergency contraceptive maker Gynetics would support age requirements and other restrictions on over-the-counter access to emergency contraception products, Gynetics Chief Financial and Operating Officer Jack Stover suggested to an FDA Rx-to-OTC switch public meeting June 29.
Gynetics Exec Supports Restricted Access For OTC Emergency Contraceptives
Emergency contraceptive maker Gynetics would support age requirements and other restrictions on over-the-counter access to emergency contraception products, Gynetics Chief Financial and Operating Officer Jack Stover suggested to an FDA Rx-to-OTC switch public meeting June 29.
Barr Will Begin First Self-Sponsored Clinical Trial For An NDA This Fall
Barr Labs will begin clinical trials on a prostate cancer therapy this fall, the first time it will be conducting its own clinical trials, Barr CEO Bruce Downey said during an Aug. 10 teleconference.